Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
MedPage Today on MSN7d
First Omalizumab Biosimilar ApprovedThe FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8539 ...
Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback